Enrichment of m6A RNA modifications in circulating tumor cells (CTCs) of lung cancer patients131 suggests the potential utility of METTL3 as a biomarker for lung cancer diagnosis, prognosis, and treatment. This evidence concerns the gene METTL3 and neoplasm.